Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Spironolactone for atrial fibrillation burden in pacemaker patients
ACTRN12616001188426Phase 4Terminated
- Sponsor
- University of Otago
- Start
- Dec 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised trial in Atrial fibrillation (AFib) comparing Spironolactone with Placebo (2 arms). Primary endpoints: Total burden of episodic atrial fibrillation, Echocardiographic left atrial remodeling and 1 more. Started Dec 2016; status: terminated.
02
Drugs
spironolactone
03
Conditions
Atrial fibrillation (AFib)
Beyond the preview
Go deeper on ACTRN12616001188426.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12616001188426.